PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics announced the approval of inducement grants for nineteen new employees on Oct. 23, 2024.

Rhea-AI Summary

PTC Therapeutics announced the approval of inducement grants for nineteen new employees on Oct. 23, 2024. The grants include 13,690 non-statutory stock options and 20,250 restricted stock units (RSUs). The stock options have an exercise price of $42.48 per share, vesting over four years with 25% vesting after the first year and 6.25% quarterly thereafter. The RSUs also vest over four years, with 25% vesting annually. These awards were granted under Nasdaq Listing Rule 5635(c)(4) as part of the new employees' compensation packages.

Positive

• Company demonstrates ability to attract new talent with equity compensation
• Stock options granted at market price ($42.48), aligning employee interests with shareholders

Negative

• Potential shareholder dilution from issuance of 33,940 new shares (options and RSUs combined)

Argus Session date unavailable

-0.66% session move Open Argus

Details

News Market Reaction – PTCT

The recorded move for PTCT in the trading session of this news was -0.66%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WARREN, N.J., Oct. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 23, 2024, the company approved non-statutory stock options to purchase an aggregate of 13,690 shares of its common stock and 20,250 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to nineteen new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

The inducement grants were approved by PTC's Compensation Committee on Oct. 23, 2024, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

All stock option awards have an exercise price of $42.48 per share, the closing price of PTC's common stock on Oct. 23, 2024, the immediately preceding trading day. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.

ABOUT PTC THERAPEUTICS, INC.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Instagram, Facebook, Twitter, and LinkedIn. 

For more information please contact:

Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302287599.html

SOURCE PTC Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options and RSUs did PTC Therapeutics (PTCT) grant on October 23, 2024?

PTC Therapeutics granted 13,690 non-statutory stock options and 20,250 RSUs to nineteen new employees.

What is the exercise price for PTCT's October 2024 stock option grants?

The stock options were granted with an exercise price of $42.48 per share, which was the closing price on October 23, 2024.

What is the vesting schedule for PTCT's October 2024 inducement grants?

The stock options vest over 4 years with 25% vesting after year one and 6.25% quarterly thereafter. RSUs vest over 4 years with 25% vesting annually.